The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.
Over the past two years, the life sciences industry has seemingly fully embraced AI. Every week, there’s a new story about a major development in the industry tied to the advanced technology. Researchers and experts have tested out the algorithmic technology across a variety of areas in pharmaceuticals, including drug development, identifying patient populations, and marketing efforts.
Now, one of the tech industry’s largest companies is partnering with multiple life sciences companies in order to advance AI even further.
NVIDIA announced these new partnerships at the 2025 JP Morgan Healthcare Conference in San Francisco. The companies listed as using NVIDIA’s tech to power AI efforts included IQVIA, Illumina, the Mayo Clinic, and the Arc Institute. According to NVIDIA’s press release, AI technology, including agents and robots, will be involved with $3 trillion in operations across the industry.
In a press release, NVIDIA’s vice president of healthcare Kimberly Powell said, “AI offers an exceptional opportunity to advance healthcare and life sciences with tools that help providers detect diseases earlier and discover new treatments faster. The combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide.”
Bhavik Patel, president of commercial solutions at IQVIA, discussed the company’s usage of NVIDIA tech. IQVIA is using NVIDIA’s AI Foundry service, NIVIDIA NIM, and NIVIDIA Blueprints across various sectors of its business. This technology will help the company handle more than 64 petabytes of information and increase its research capabilities.
In the same press release, Patel said, “This represents a significant leap forward in how we apply AI to healthcare and life sciences. We are excited to combine our industry-leading capabilities and a decade of experience in artificial intelligence with NVIDIA’s advanced AI technologies to build new solutions powered by AI agents that are trained on world-class healthcare information and optimized for life sciences workflows. This collaboration will advance our mission to help our clients accelerate innovation and treatments to market.”
One area where AI is expected to have a huge impact is genomic research. This sort of work produces mountains of data, which can cause difficulties for the researchers working with it. AI, however, can sort, analyze, and find patterns in the data much faster than any human could, saving researchers precious time.
Illumina, a DNA sequencing and informatics technology company, is incorporating NVIDIA’s technology into its pipeline to do just that.
Steve Barnard, chief technology officer at Illumina, discussed the partnership, saying, “Our ability to combine the power of AI with multiomics data is revolutionizing how we can understand disease. By combining Illumina’s expertise in genomics data and analysis with NVIDIA’s powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing lifesaving therapies.”